Alterity Therapeutics Lim... (ATHE)
3.45
-0.05 (-1.43%)
At close: Mar 28, 2025, 11:41 AM
Company Description
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia.
The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease.
It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease.
The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019.
Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
Alterity Therapeutics Limited

Country | AU |
IPO Date | Sep 29, 2003 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 10 |
CEO | Dr. David A. Stamler M.D. |
Contact Details
Address: 460 Bourke Street Melbourne, VIC AU | |
Website | https://alteritytherapeutics.com |
Stock Details
Ticker Symbol | ATHE |
Exchange | NASDAQ |
Fiscal Year | July - June |
Reporting Currency | USD |
CIK Code | 0001131343 |
CUSIP Number | 02155X106 |
ISIN Number | US02155X2053 |
Employer ID | 00-0000000 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. David A. Stamler M.D. | Chief Executive Officer |
Abby Macnish Niven B.Com., B.Sc., C.F.A. | Chief Financial Officer & Company Secretary |
Dr. Robert Cherny | Head of Research |
Dr. Rudolph Emile Tanzi Ph.D. | Chief Scientific Advisor and Member of Research & Development Advisory Board |
Dr. Steven D. Targum M.D. | Chief Medical Advisor |
Geoffrey Paul Kempler B.Sc. | Co-Founder & Non-Executive Chairman |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 27, 2025 | 6-K | Filing |
Mar 25, 2025 | 6-K | Filing |
Mar 14, 2025 | 6-K | Filing |
Mar 14, 2025 | 6-K | Filing |
Feb 28, 2025 | 6-K | Filing |
Feb 28, 2025 | 6-K | Filing |
Feb 24, 2025 | 6-K | Filing |
Feb 19, 2025 | 6-K | Filing |
Feb 18, 2025 | 6-K | Filing |
Feb 18, 2025 | 6-K | Filing |